Chimerix(CMRX) - 2019 Q3 - Quarterly Report

Financial Performance - Contract revenue for Q3 2019 was $1,958,000, compared to $369,000 in Q3 2018, representing a 431% increase[14] - Total operating expenses for Q3 2019 were $76,522,000, significantly up from $17,079,000 in Q3 2018, marking a 348% increase[14] - Net loss for Q3 2019 was $73,730,000, compared to a net loss of $16,079,000 in Q3 2018, reflecting a 359% increase in losses[14] - The comprehensive loss for Q3 2019 was $73,766,000, compared to $15,899,000 in Q3 2018, representing a 365% increase[14] - For the nine months ended September 30, 2019, the net loss was $109,073,000, compared to a net loss of $54,518,000 for the same period in 2018, representing a 100% increase in net loss[19] - Net cash used in operating activities for the nine months ended September 30, 2019, was $71,712,000, an increase from $45,425,000 in the prior year, indicating a 58% increase in cash outflow[19] - Total operating expenses for the three months ended September 30, 2019, were $76.5 million, a significant increase of 348.0% from $17.1 million in the same period in 2018[131] - The net loss for the three months ended September 30, 2019, was $73.7 million, representing a 358.5% increase from a net loss of $16.1 million in the same period in 2018[131] Research and Development - Research and development expenses for the nine months ended September 30, 2019, were $34,795,000, down from $39,963,000 for the same period in 2018, indicating a 13% decrease[14] - Research and development expenses for the three months ended September 30, 2019, were $7.5 million, a decrease of 37.3% from $11.9 million in the same period in 2018[131] - The company incurred $65,045,000 in acquired in-process research and development expenses in Q3 2019, with no such expenses reported in Q3 2018[14] - Acquired in-process research and development expenses totaled $65.0 million for the three months ended September 30, 2019, including a $30.0 million upfront payment to Cantex[137] - The company is focused on two clinical-stage product candidates: dociparstat sodium (DSTAT) and brincidofovir (BCV), aiming to advance innovative medicines for cancer and serious diseases[23] - DSTAT has shown potential in enhancing event-free survival and overall survival in a Phase 2 study, indicating promising clinical outcomes[23] - The company plans to initiate a Phase 3 clinical trial of DSTAT for AML treatment in mid-2020, pending an end-of-phase 2 meeting with the U.S. FDA[104] - The company is focused on the treatment of smallpox with BCV, having discontinued development for other indications[85] Assets and Liabilities - Total liabilities increased to $15,803,000 as of September 30, 2019, from $13,110,000 at the end of 2018, a rise of 20.5%[13] - Stockholders' equity decreased to $111,948,000 as of September 30, 2019, down from $177,604,000 at the end of 2018, a decline of 37%[13] - The company had cash and cash equivalents of $19,349,000 at the end of the period, down from $22,991,000 at the end of September 30, 2018[19] - The total present value of lease payments was $982,000, with future minimum rental payments totaling $1,077,000[56] - The company’s total investments amounted to $97,366 thousand as of September 30, 2019, with corporate bonds, U.S. treasury securities, and commercial paper included in this total[48] Contracts and Agreements - The Company may receive up to $75.8 million in expense reimbursement and $5.3 million in fees under the BARDA contract for the advanced development of BCV[38] - The Company entered into a license agreement with SymBio Pharmaceuticals for a fixed transaction amount of $5.0 million and potential variable amounts up to $180 million based on regulatory and commercial milestones[39] - The company entered into a license agreement with SymBio for exclusive worldwide rights to develop, manufacture, and commercialize BCV, with an upfront payment of $5.0 million due by October 22, 2019, and potential milestone payments of up to $180.0 million[81] - The company made an upfront cash payment of $30.0 million to Cantex Pharmaceuticals for the acquisition of DSTAT, along with issuing 10.0 million shares of common stock[79] - The company is obligated to pay Cantex regulatory milestone payments of up to $202.5 million and sales milestone payments of up to $385.0 million upon achieving specified net sales levels[79] Workforce and Restructuring - The company has restructured operations, resulting in a workforce reduction of 43 employees and incurring restructuring costs totaling $6.3 million for the nine months ended September 30, 2019[88] Future Outlook and Risks - The company expects to continue incurring significant losses and negative cash flows for the foreseeable future, depending on future expenditures and revenue generation capabilities[172] - The company may need to raise additional capital to pursue the development and commercialization of DSTAT and other product candidates, which could involve unfavorable terms[184] - The company has not completed development of any product candidates and anticipates incurring substantial expenses related to regulatory approvals and manufacturing capabilities[172] - The success of the company's product candidates depends on various factors, including the acceptance of clinical data by regulatory authorities and the ability to establish manufacturing capabilities[190] - The company acknowledges that unforeseen events during clinical trials could adversely affect the completion and success of its product candidates[197] - Regulatory approval for DSTAT and BCV is uncertain, and any delays could reduce the exclusive commercialization period and allow competitors to enter the market sooner[203] - Clinical trials may require a larger number of subjects than anticipated, and enrollment may be slower than expected, impacting trial timelines[202] - The cost of clinical trials may exceed initial estimates, affecting overall development budgets[201] - Any serious side effects from approved products could lead to withdrawal of approval or additional restrictions on distribution[206]